This site is intended for health professionals only
Wednesday 22 May 2019
Share |

Industry News

Six in 10 pharmacy professionals in favour of banning homeopathy prescribing

Friday 7th September 2018

Six in 10 pharmacy professionals are against the sale and dispensing of homeopathic products, pharmacists at an international conference have heard.
In a congress session taking place at the International Pharmaceutical Federation’s (FIP) World Congress of Pharmacy and Pharmaceutical Science on Tuesday (4 September), 63% of between 150 to 200 people surveyed said ‘...

Thu, 19 Mar 2015
Neubourg Pharma UK announces the launch of Allpresan Diabetic Foot Foam Creams into the UK, clinically formulated to treat and prevent dry cracked skin and calluses on diabetic feet, the first clinically and medically approved to be used between toes safely.
Thu, 19 Mar 2015
Ablynx announced that it has administered the first dose in the Phase IIb study to evaluate the efficacy and safety of its anti-IL-6R Nanobody®, ALX-0061, administered subcutaneously in combination with methotrexate (MTX) in adult patients with active RA, despite MTX therapy. The study aims to identify the optimum dose and frequency of administration of ALX-0061 for the next phases of development.
Thu, 19 Mar 2015
Despite requests by government agencies, no manufacturer has so far developed a child-friendly preparation of 13-cis-retinoic acid (13-CRA), which is needed to improve children’s treatment and protect unborn children.
Wed, 11 Mar 2015
New data presented show that Tresiba® (insulin degludec) improves blood glucose control, reduces the risk of hypoglycaemia and allows for dose reductions in certain patients. (1) These are the first real world data to show the value of insulin degludec in clinical practice across all five countries that prescribe the drug, including the UK, and support insulin degludec clinical trial data.
Tue, 10 Mar 2015
Ropeginterferon alfa 2b is a novel, long-acting, mono-pegylated Interferon, administered only once every 14 days, after achieving therapy response even only monthly. Based on previous Phase I/II trials, Ropeginterferon alfa 2b is expected to be safe and effective in the majority of PV patients. Haematological and molecular responses occured in most patients; moreover, several patients achieved undetectable mutated JAK2 levels and a complete normalisation of their chromosomal make-up.
Tue, 10 Mar 2015
The treatment, which was developed to treat cancers such as leukaemia and lymphoma and is being used at the Royal Hallamshire Hospital, Sheffield, is the first to significantly reverse disability of MS in certain patients.
Tue, 10 Mar 2015
VTE is a term used to describe deep vein thrombosis (DVT) and pulmonary embolism (PE). When a blood clot forms in one of the deep veins in the leg, thigh, pelvis or arm it is known as a DVT. If part of the blood clot comes loose it can be carried in the blood to another part of the body where it can cause problems. If the blood clot reaches the lungs (PE), it can be fatal.

You are leaving

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?


Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.



Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher